The Impact of Sedation on Cardio-Cerebrovascular Adverse Events after Surveillance Esophagogastroduodenoscopy in Patients with Gastric Cancer: A Nationwide Population-Based Cohort Study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The impact of sedation on cardio-cerebrovascular (CCV) adverse events after esophagogastroduodenoscopy (EGD) in patients with gastric cancer (GC) is unclear. We investigated the incidence rate and impact of sedation on CCV adverse events after surveillance EGD in patients with GC. Methods: We performed a nationwide population-based cohort study using the Health Insurance Review and Assessment Service databases from January 1, 2018, to December 31, 2020. Using a propensity score-matched analysis, patients with GC were divided into two groups: sedative agent users and nonusers for surveillance EGD. We compared the occurrence of CCV adverse events within 14 days between the two groups. Results: Of the 103,463 patients with GC, newly diagnosed CCV adverse events occurred in 2.57% of patients within 14 days after surveillance EGD. Sedative agents were used in 41.3% of the patients during EGD. The incidence rates of CCV adverse events with and without sedation were 173.6/10,000 and 315.4/10,000, respectively. Between sedative agent users and nonusers based on propensity score matching (28,008 pairs), there were no significant differences in the occurrence of 14-day CCV, cardiac, cerebral, and other vascular adverse events (2.28% vs 2.22%, p=0.69; 1.44% vs 1.31%, p=0.23; 0.74% vs 0.84%, p=0.20; 0.10% vs 0.07%, p=0.25, respectively). Conclusions: Sedation during surveillance EGD was not associated with CCV adverse events in patients with GC. Therefore, the use of sedative agents may be considered in patients with GC during surveillance EGD without excessive concerns about CCV adverse events.
Abstract
Background/Aims: The impact of sedation on cardio-cerebrovascular (CCV) adverse events after esophagogastroduodenoscopy (EGD) in patients with gastric cancer (GC) is unclear. We investigated the incidence rate and impact of sedation on CCV adverse events after surveillance EGD in patients with GC. Methods: We performed a nationwide population-based cohort study using the Health Insurance Review and Assessment Service databases from January 1, 2018, to December 31, 2020. Using a propensity score-matched analysis, patients with GC were divided into two groups: sedative agent users and nonusers for surveillance EGD. We compared the occurrence of CCV adverse events within 14 days between the two groups. Results: Of the 103,463 patients with GC, newly diagnosed CCV adverse events occurred in 2.57% of patients within 14 days after surveillance EGD. Sedative agents were used in 41.3% of the patients during EGD. The incidence rates of CCV adverse events with and without sedation were 173.6/10,000 and 315.4/10,000, respectively. Between sedative agent users and nonusers based on propensity score matching (28,008 pairs), there were no significant differences in the occurrence of 14-day CCV, cardiac, cerebral, and other vascular adverse events (2.28% vs 2.22%, p=0.69; 1.44% vs 1.31%, p=0.23; 0.74% vs 0.84%, p=0.20; 0.10% vs 0.07%, p=0.25, respectively). Conclusions: Sedation during surveillance EGD was not associated with CCV adverse events in patients with GC. Therefore, the use of sedative agents may be considered in patients with GC during surveillance EGD without excessive concerns about CCV adverse events.
참고문헌 (46)
- Dicken BJ, "Gastric adenocarcinoma : review and considerations for future directions", Ann Surg, 241, pp.27~39 (2005)
- Pang HY, "Detection of asymptomatic recurrence following curative surgery improves survival in patients with gastric cancer : a systematic review and meta-analysis", Front Oncol, 12, pp.1011683~ (2022)
- Ajani JA, "Gastric Cancer, Version 2. 2022, NCCN Clinical Practice Guidelines in Oncology", J Natl Compr Canc Netw, 20, pp.167~192 (2022)
- Smyth EC, "Gastric cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 27(suppl 5), pp.v38~v49 (2016)
- Japanese Gastric Cancer Association, "Japanese gastric cancer treatment guidelines 2014(ver. 4)", Gastric Cancer, 20, pp.1~19 (2017)
- Lee JH, "Clinical practice guidelines for gastric cancer in Korea : an evidence-based approach", J Gastric Cancer, 14, pp.87~104 (2014)
- D'Ugo D, "Follow-up : the evidence", Dig Surg, 30, pp.159~168 (2013)
- Jang JM, "Gastrointestinal and non-gastrointestinal complication rates associated with diagnostic esophagogastroduodenoscopy under sedation", Medicine(Baltimore), 101, pp.e29266~ (2022)
- Kim SY, "Impacts of age and sedation on cardiocerebrovascular adverse events after diagnostic GI endoscopy : a nationwide population-based study", Gastrointest Endosc, 92, pp.591~602 (2020)
- Sharma VK, "A national study of cardiopulmonary unplanned events after GI endoscopy", Gastrointest Endosc, 66, pp.27~34 (2007)
- Cohen LB, "Endoscopic sedation in the United States : results from a nationwide survey", Am J Gastroenterol, 101, pp.967~974 (2006)
- Gangi S, "Cardiovascular complications after GI endoscopy : occurrence and risks in a large hospital system", Gastrointest Endosc, 60, pp.679~685 (2004)
- Leffler DA, "The incidence and cost of unexpected hospital use after scheduled outpatient endoscopy", Arch Intern Med, 170, pp.1752~1757 (2010)
- Kwon S, "Thirty years of national health insurance in South Korea : lessons for achieving universal health care coverage", Health Policy Plan, 24, pp.63~71 (2009)
- Kim JA, "Towards actualizing the value potential of Korea Health Insurance Review and Assessment(HIRA)data as a resource for health research : strengths, limitations, applications, and strategies for optimal use of HIRA data", J Korean Med Sci, 32, pp.718~728 (2017)
- Brämer GR, "International statistical classification of diseases and related health problems. Tenth revision", World Health Stat Q, 41, pp.32~36 (1988)
- "Guideline for Pharmaceutical Serialization System, the first edition" (2015)[URL]
- Day LW, "Adverse events in older patients undergoing colonoscopy : a systematic review and meta-analysis", Gastrointest Endosc, 74, pp.885~896 (2011)
- Nasu J, "Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resection", Endoscopy, 37, pp.990~993 (2005)
- Kato M, "Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer : a multicentre retrospective cohort study by Osaka University ESD study group", Gut, 62, pp.1425~1432 (2013)
- Ajani JA, "Gastric cancer", J Natl Compr Canc Netw, 8, pp.378~409 (2010)
- Zhou J, "Influence of sedation on the detection rate of early cancer and precancerous lesions during diagnostic upper gastrointestinal endoscopies : a multicenter retrospective study", Am J Gastroenterol, 116, pp.1230~1237 (2021)
- McQuaid KR, "A systematic review and metaanalysis of randomized, controlled trials of moderate sedation for routine endoscopic procedures", Gastrointest Endosc, 67, pp.910~923 (2008)
- Riphaus A, "Endoscopic sedation and monitoring practice in Germany : results from the first nationwide survey", Z Gastroenterol, 48, pp.392~397 (2010)
- Uedo N, "Differences in routine esophagogastroduodenoscopy between Japanese and international facilities : a questionnaire survey", Dig Endosc, 28(Suppl 1), pp.16~24 (2016)
- Park HJ, "2021 Korean Society of Gastrointestinal Endoscopy Clinical Practice Guidelines for Endoscopic Sedation", Gut Liver, 16, pp.341~356 (2022)
- Eckardt VF, "Complications and adverse effects of colonoscopy with selective sedation", Gastrointest Endosc, 49, pp.560~565 (1999)
- Iber FL, "Evaluation of complications during and after conscious sedation for endoscopy using pulse oximetry", Gastrointest Endosc, 39, pp.620~625 (1993)
- Yetkin G, "Effects of sedation during upper gastrointestinal endoscopy on endocrine response and cardiorespiratory function", Braz J Med Biol Res, 40, pp.1647~1652 (2007)
- Oei-Lim VL, "Cardiovascular responses, arterial oxygen saturation and plasma catecholamine concentration during upper gastrointestinal endoscopy using conscious sedation with midazolam or propofol", Eur J Anaesthesiol, 15, pp.535~543 (1998)
- Osinaike BB, "Cardiorespiratory changes during upper gastrointestinal endoscopy", Afr Health Sci, 7, pp.115~119 (2007)
- Wang CY, "Hypoxia during upper gastrointestinal endoscopy with and without sedation and the effect of pre-oxygenation on oxygen saturation", Anaesthesia, 55, pp.654~658 (2000)
- Hart R, "Complications of diagnostic gastrointestinal endoscopy", Endoscopy, 22, pp.229~233 (1990)
- Travis AC, "Endoscopy in the elderly", Am J Gastroenterol, 107, pp.1495~1501 (2012)
- Lippert E, "Gastrointestinal endoscopy in patients aged 75 years and older : risks, complications, and findings : a retrospective study", Int J Colorectal Dis, 30, pp.363~366 (2015)
- Clarke GA, "The indications, utilization and safety of gastrointestinal endoscopy in an extremely elderly patient cohort", Endoscopy, 33, pp.580~584 (2001)
- ASGE Standards of Practice Committee, "Modifications in endoscopic practice for the elderly", Gastrointest Endosc, 78, pp.1~7 (2013)
- Jafri SM, "Endoscopy in the elderly : a review of the efficacy and safety of colonoscopy, esophagogastroduodenoscopy, and endoscopic retrograde cholangiopancreatography", J Clin Gastroenterol, 44, pp.161~166 (2010)
- Ure T, "Colonoscopy in the elderly. Low risk, high yield", Surg Endosc, 9, pp.505~508 (1995)
- Arora G, "Risk of perforation from a colonoscopy in adults : a large population-based study", Gastrointest Endosc, 69(3Pt 2), pp.654~664 (2009)
- Ross R, "Heart rate and blood pressure changes during gastroscopy in healthy older subjects", Gerontology, 50, pp.182~186 (2004)
- Rapsomaniki E, "Blood pressure and incidence of twelve cardiovascular diseases : lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people", Lancet, 383, pp.1899~1911 (2014)
- Navar-Boggan AM, "Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease", Circulation, 131, pp.451~458 (2015)
- Song F, "Clinical, sonographic characteristics and long-term prognosis of valvular heart disease in elderly patients", J Geriatr Cardiol, 16, pp.33~41 (2019)
- d'Arcy JL, "Valvular heart disease : the next cardiac epidemic", Heart, 97, pp.91~93 (2011)
- Lim H, "Clinical practice guideline for the management of antithrombotic agents in patients undergoing gastrointestinal endoscopy", Clin Endosc, 53, pp.663~677 (2020)